Description : KLab is a family of 850 employees under the leadership of a dynamic and enthusiastic team which incorporates innovative strategies, latest technologies and unique products to achieve rapid growth. Klab has a charged work culture where every individual is respected and given an opportunity to optimally utilize his creativity and individuality to achieve excellence. This approach has contributed in providing the Pharma Industry with some of the most creative and successful professionals and entrepreneurs.


Klab is growing at 19% as per IMS/ORG and 35% internally due to launch of unique patented Novel Drug Delivery Systems as also latest molecules. In the last 2 years Klab has reached the 65th rank in IMS/ORG from a 107th rank a few years ago.


Post January 2005, only companies with product patents will be able to launch new products. Klab has filed more than 50 patents. Most of the Klab products are unique and patented. For example Klab has launched Cefixime Once a Day for the first time in the world. Klab has received a US Patent for its Alendronate NDDS. Klab plans to market Liposomal Doxorubicin very shortly.